share_log

Chardan Capital Maintains Buy on Senti Biosciences, Lowers Price Target to $6

Benzinga ·  May 11, 2023 13:08

Chardan Capital analyst Geulah Livshits maintains Senti Biosciences (NASDAQ:SNTI) with a Buy and lowers the price target from $7 to $6.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment